Oral Fluoroquinolone Use and the Risk of Acute Liver Injury: A Nationwide Cohort Study

Olof Nibell,1 Henrik Svanström,2 and Malin Inghammar1

1Section for Infection Medicine, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; and 2Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark

Background. Antibiotics are considered to be among the most frequent causes of drug-related acute liver injury (ALI). Although many ALIs have mild and reversible clinical outcomes, there is substantial risk of severe reactions leading to acute liver failure, need for liver transplant, and death. Recent studies have raised concerns of hepatotoxic potential related to the use of fluoroquinolones.

Methods. This study examined the risk of ALI associated with oral fluoroquinolone treatment compared with amoxicillin (419 930 courses, propensity score matched 1:1). The information on drug use was collected from a national, registry-based cohort derived from all Swedish adults aged 40–85 years.

Results. During a follow-up period of 60 days, users of oral fluoroquinolones had a >2-fold risk of ALI compared to users of amoxicillin (hazard ratio, 2.32 [95% confidence interval {CI}, 1.01–5.35). The adjusted absolute risk difference for use of fluoroquinolones as compared to amoxicillin was 4.94 (95% CI, .04–16.3) per 1 million episodes.

Conclusions. In this propensity score–matched study, fluoroquinolone treatment was associated with an increased risk of ALI in the first 2 months after starting treatment.

Keywords. ALI; DILI; fluoroquinolones; hepatotoxic; liver injury.

Many hepatotoxic drug reactions are predictable or dose dependent, and thus preventable to some degree. Other hepatotoxic drug reactions, however, are unpredictable and independent of dose and duration of treatment. This type of event is commonly referred to as an idiosyncratic drug-induced liver injury (DILI) and is considered the main cause of acute liver injury (ALI) [1]. These rare but potentially life-threatening events are associated with clinical outcomes ranging from minor elevations in liver enzymes to transient liver failure, need for liver transplant, and death. Due to the innate unpredictability of idiosyncratic drug reactions as well as the difficulty in establishing causality, they are often not discovered until the drug is released to the general public and used in larger populations. In a summary of 5 large prospective and retrospective studies on DILI, anti-infectives were the most common attributable cause, accounting for proportions ranging from 27% to 65% of all cases of DILI [2]. Population-based estimates for all DILIs have been reported in studies conducted in France (2002) and Iceland (2013) with an incidence rate of 13.9 and 19.1 per 100 000, respectively [3, 4]. In the latter study, it was estimated that 1 in 2300 users of amoxicillin–clavulanate and 1 in 1369 users of nitrofurantoin developed liver injuries.

Fluoroquinolones are a family of broad-spectrum antibiotics covering an array of both gram-positive and gram-negative bacteria. It is one of the most widely used classes of systemic antibiotics, reaching almost 23 million unique prescriptions per year in the United States alone [5]. The fluoroquinolones exhibit antibacterial properties by inhibiting the bacterial DNA synthesis by targeting the microbe’s DNA topoisomerase and DNA gyrase [6]. Although the drug is not generally considered to interact with host DNA, adverse effects such as tendinopathy and QT-interval prolongation are well established [7–9]. There have been safety concerns with regard to hepatic toxicity in the past decades. Owing to case reports of a possible association with ALI, trovafloxacin and temafloxacin were both withdrawn in the 1990s [10, 11]. A few observational studies have been published reporting an up to 3-fold increase in risk of ALI associated with fluoroquinolone treatment. However, these estimates are primarily based on case-control studies with limited ability to control for underlying differences in health status, so it cannot be ruled out that the observed increased risk is not attributable to fluoroquinolone use. Furthermore, considering the potential severity of hepatotoxic drug reactions and the widespread use of fluoroquinolones, further investigation is warranted.

We conducted a nationwide register-based cohort study in Sweden to assess whether oral fluoroquinolone treatment was associated with an increased risk of ALI.
METHODS

Study Design
We conducted a register-based cohort study based on a historical cohort of all Swedish adults 40–85 years of age, July 2006–January 2014, linking individual data from national healthcare registries. We investigated the risk of ALI in users of oral fluoroquinolones by collecting individual information and prescription data for patients either seeking medical care for, or having as a cause of death, diagnoses of ALI within 60 days after start of drug use. We considered each prescription as a separate event, meaning an individual could contribute with >1 prescription to the study. Index date was based on date of filling a study drug prescription. To control for confounding by indication, we used an active comparator design with amoxicillin as the reference drug. Amoxicillin has a safe hepatic profile with relatively few case reports describing liver-related injuries [12, 13]. In addition, it has medical indications overlapping those of fluoroquinolones. To control for potential differences in baseline health status, we used a propensity score–matched design comprised of a large number of covariates. Linking of registries was done using the national unique personal identification numbers assigned to all Swedish citizens.

Data Sources
Prescription data on fluoroquinolones (Anatomical Therapeutic Chemical [ATC] code J01MA) and amoxicillin (ATC code J01CA04) was collected using the Swedish Prescribed Drug Register, which contains comprehensive coverage (date of filling prescription, size of prescription, dosage, etc) of all drugs dispensed at Swedish pharmacies from July 2005 onward [14]. Outcome data were collected from the National Patient Register, which holds information on all hospital admissions, outpatient visits, and emergency department visits as well as from the National Cause of Death Register, which holds information on all causes of death according to the International Classification of Diseases, Tenth Revision (ICD-10). In addition, data for estimations of baseline differences in health (ie, demographic data and information on healthcare and drug usage) were collected from the National Patient Register as well as from the Total Population Register, which holds demographic information on all Swedish residents [15].

Study Cohort
From the source population of all Swedish adults, 40–85 years of age in the July 2006 to January 2014 time period, we identified all treatment courses of oral fluoroquinolones or amoxicillin. We excluded courses in patients who had filled a prescription for any of the study drugs in the past 2 months, had multiple filled prescriptions of different study drugs on the date of filling prescription (index date), or had been hospitalized in the past 2 months. To reduce confounding, we also excluded courses in patients with a history of acute hepatitis (including infectious) in the past 2 months who had previously been diagnosed with hepatic or biliary cancer, previously diagnosed with any other hepatobiliary disease (including chronic hepatitis) or liver transplant, with a history of human immunodeficiency virus/AIDS, and with predefined end-stage illness, who may have had a high pretreatment risk of ALI. To assure adequate covariate ascertainment, we also excluded courses from patients with no prescriptions for any drug in the past year preceding the index date. See Supplementary Table 1 and Figure 1 for details.

Propensity Score Model
To reduce the influence of confounding from differences in baseline health status, we used propensity score matching. Logistic regression, including a total of 43 covariates as predictors, was used to calculate the propensity to receive fluoroquinolone therapy. The greedy 1 to >5 digit propensity score–matching algorithm was used to match fluoroquinolone and amoxicillin use on a 1:1 ratio [16]. To estimate covariate balancing after matching, we used standardized differences, considering a value ≤0.10 as being well balanced [17]. Missing values were present in the “region of residence” category (0.2%) and were handled by including a missing value category [18]. A complete list of predictors included in the propensity score calculation is included in Supplementary Table 2.

Follow-up and Outcome
Data from the Drug Induced Liver Injury Network between 2004 and 2010 indicate that the majority of adverse events occur within weeks after start of treatment [19]. Therefore, the main analysis and follow-up interval was determined as 1–60 days after filling a prescription. Follow-up started on the date of filling prescription of an index drug and ended on end of study (1 January 2014), participant reaching age 86, hospitalization or death due to any of the primary outcome diagnoses, or 60 days after filling the prescription, whichever occurred first. The 60-day risk period was divided into 10-day intervals, to explore the timing of events.

The primary outcome, ALI, was defined as toxic liver disease (ICD-10 codes K710, K711, K712, K716, K719), or acute and subacute liver failure (ICD-10 codes K720, K729), recorded either in the National Patient Register or in the National Cause of Death Register [20, 21]. The ICD-10 codes are listed in Supplementary Table 3.

Statistical Analyses
We used Cox regression to calculate hazard ratios (HRs) comparing the risk of ALI between users of fluoroquinolones and users of amoxicillin. An individual could contribute with person-time from >1 treatment course unless an outcome event occurred or study end (January 2014) or end of follow-up (60 days) was reached, ensuring that the courses never overlapped. HRs were also estimated in subgroups of participants.
classified according to sex and age. To estimate homogeneity between the subgroup estimates, we used likelihood ratio tests. As a secondary analysis, Cox regression was used to estimate HRs for all-cause mortality to assess residual confounding from differences in disease severity or underlying health status. Proportional hazards assumption was assessed by evaluating the interaction between treatment status and time scale using Wald test [22]. We estimated the absolute rate difference for the 60-day period as (hazard ratio – 1) × incidence in the amoxicillin group, presented as number of cases per 1 million treatment episodes [23]. The adjusted absolute difference in risk per 1 million episodes of fluoroquinolone use was estimated by multiplying the sum of the adjusted HR minus 1, with the crude rate in users of amoxicillin (see Supplementary Materials for details). All statistical tests were 2-sided where a 95% confidence interval (CI) not overlapping 1.0 and a P value < .05 were considered statistically significant. Statistical analyses were performed using SAS version 9.4 software (SAS Institute, Cary, North Carolina).

Ethical Considerations
The study was approved by the Regional Ethics Committee in Lund (Dnr: 2013/717).

RESULTS

Cohort
During the study period, we identified 1,542,175 courses of oral fluoroquinolone treatment and 914,726 courses of amoxicillin use. The inclusion criteria were met for 720,975 courses of oral fluoroquinolone treatment and 549,084 courses of amoxicillin use. The cohort flowchart is displayed in Figure 1. After applying propensity score matching in a 1:1 ratio, there remained 419,930 courses of fluoroquinolones and amoxicillin. The characteristics were well balanced between the users of fluoroquinolones and the users of amoxicillin (Table 1). The most commonly used fluoroquinolone was ciprofloxacin (79.3%), followed by norfloxacin (17.4%), moxifloxacin (1.78%), levofloxacin (1.11%), and ofloxacin (0.47%). The mean follow-up time in the main (1–60 days) interval was 58.1 days (standard deviation [SD], 8.5 days) in the amoxicillin group and 57.6 days (SD, 9.4 days) in the fluoroquinolone group. Due to switch to another antibiotic, 14.6% of amoxicillin users and 21.3% ciprofloxacin users were censored. Among users of amoxicillin and ciprofloxacin, 10.4% and 12.9%, respectively, were censored due to hospitalization. The difference in proportion of hospitalization in ciprofloxacin users was attributed to admissions for
### Table 1. Baseline Characteristics of the Matched Cohort

| Characteristic                                                                 | Amoxicillin, No. (%) | Fluoroquinolones, No. (%) | Standardized Difference |
|-------------------------------------------------------------------------------|----------------------|---------------------------|-------------------------|
| No. in cohort                                                                 | 419,930              | 419,930                   |                         |
| Male sex                                                                      | 208,235 (49.6)       | 208,139 (49.6)            | <0.10                   |
| Age                                                                           | 63.1 (11.5)          | 63.1 (11.7)               | <0.10                   |
| Year                                                                          |                      |                           |                         |
| 2006–2007                                                                     | 95,462 (22.7)        | 110,896 (26.4)            | <0.10                   |
| 2008–2009                                                                     | 120,530 (28.7)       | 115,279 (27.5)            | <0.10                   |
| 2010–2011                                                                     | 109,581 (26.1)       | 102,154 (24.3)            | <0.10                   |
| 2012–2013                                                                     | 94,357 (22.5)        | 91,599 (21.8)             | <0.10                   |
| Region of residence                                                          |                      |                           |                         |
| Stockholm metropolitan area                                                   | 106,801 (25.4)       | 106,637 (25.4)            | <0.10                   |
| Rest of mid-Sweden                                                           | 76,341 (18.2)        | 76,362 (18.2)             | <0.10                   |
| Southern Sweden metropolitan areas                                           | 74,112 (17.6)        | 74,239 (17.7)             | <0.10                   |
| Rest of southern Sweden                                                       | 129,445 (30.8)       | 129,542 (30.8)            | <0.10                   |
| Northern Sweden                                                               | 32,597 (7.8)         | 32,517 (7.7)              | <0.10                   |
| Missing                                                                       | 634 (0.2)            | 632 (0.2)                 | <0.10                   |
| Underlying illnesses/recent procedures                                       |                      |                           |                         |
| Acute coronary syndrome                                                       | 14,541 (3.5)         | 14,370 (3.4)              | <0.10                   |
| Other ischemic heart disease                                                  | 40,093 (9.5)         | 39,629 (9.4)              | <0.10                   |
| Heart failure/cardiovascular disease                                          | 18,872 (4.5)         | 18,314 (4.4)              | <0.10                   |
| Cerebrovascular disease                                                       | 21,087 (5.0)         | 21,097 (5.0)              | <0.10                   |
| Arterial disease                                                              | 10,516 (2.5)         | 10,377 (2.5)              | <0.10                   |
| Respiratory disease                                                           | 42,375 (10.1)        | 41,579 (9.9)              | <0.10                   |
| Cancer                                                                        | 43,811 (10.4)        | 44,416 (10.6)             | <0.10                   |
| Cancer in the previous year                                                   | 29,666 (7.1)         | 30,206 (7.2)              | <0.10                   |
| Renal disease                                                                 | 12,061 (2.9)         | 11,880 (2.8)              | <0.10                   |
| Rheumatic disease                                                             | 18,360 (4.4)         | 18,033 (4.3)              | <0.10                   |
| Other psychiatric disorder                                                    | 32,471 (7.7)         | 32,440 (7.7)              | <0.10                   |
| Liver procedure                                                               | 345 (0.1)            | 373 (0.1)                 | <0.10                   |
| Biliary procedure                                                             | 220 (0.1)            | 225 (0.1)                 | <0.10                   |
| Pancreatic procedure                                                          | 157 (0.0)            | 152 (0.0)                 | <0.10                   |
| Concomitant drug use                                                           |                      |                           |                         |
| Platelet inhibitors                                                           | 94,860 (22.6)        | 94,677 (22.5)             | <0.10                   |
| Anticoagulants                                                                | 27,064 (6.4)         | 27,037 (6.4)              | <0.10                   |
| Lipid-lowering drugs                                                          | 109,269 (26.0)       | 109,064 (26.0)            | <0.10                   |
| Oral antidiabetic drugs                                                       | 32,914 (7.8)         | 32,787 (7.8)              | <0.10                   |
| Insulin                                                                       | 21,343 (5.2)         | 21,634 (5.2)              | <0.10                   |
| Antidepressants                                                               | 74,438 (17.7)        | 74,234 (17.7)             | <0.10                   |
| Antipsychotics                                                                | 10,100 (2.4)         | 10,066 (2.4)              | <0.10                   |
| Anxiolytics, hypnotics, and sedatives                                         | 124,487 (29.6)       | 124,163 (29.6)            | <0.10                   |
| Acetaminophen                                                                 | 121,291 (28.9)       | 121,112 (28.8)            | <0.10                   |
| Oral corticosteroids                                                          | 70,061 (16.7)        | 69,158 (16.5)             | <0.10                   |
| NSAIDs                                                                        | 131,289 (31.3)       | 131,086 (31.2)            | <0.10                   |
| Opiates                                                                       | 95,888 (22.8)        | 95,592 (22.8)             | <0.10                   |
| Systemic hormone replacement therapy                                         | 66,334 (15.8)        | 65,228 (15.5)             | <0.10                   |
| Antibiotic use within the previous 120 days                                    | 157,819 (37.6)       | 159,025 (37.9)            | <0.10                   |
| No. of concomitant drugs used in the previous year                            |                      |                           |                         |
| 1–2                                                                          | 95,612 (22.8)        | 95,791 (22.8)             | <0.10                   |
| 3–5                                                                          | 128,056 (30.5)       | 128,209 (30.5)            | <0.10                   |
| 6–9                                                                          | 114,509 (27.3)       | 114,740 (27.3)            | <0.10                   |
| ≥10                                                                          | 81,753 (19.5)        | 81,190 (19.3)             | <0.10                   |
| Healthcare usage                                                              |                      |                           |                         |
| Hospitalization due to non-hepatobiliary causes in the previous year           | 141,089 (33.6)       | 141,323 (33.7)            | <0.10                   |
| Outpatient contact due to non-hepatobiliary causes in the previous year        | 236,023 (56.2)       | 235,664 (56.1)            | <0.10                   |
| ED visit in the previous 30 days                                               | 22,552 (5.4)         | 23,177 (5.5)              | <0.10                   |

Abbreviations: ED, emergency department; NSAID, nonsteroidal anti-inflammatory drug; SD, standard deviation.
urinary tract infections according to discharge codes. The proportional hazards assumption was not violated ($P = .09$).

**Main Results**
During follow-up, there were 18 events in the fluoroquinolone group and 8 in the amoxicillin group during the main (1–60 days) period (incidence rate, 2.98/10 000 and 1.27/10 000 person-years, respectively). The cumulative incidence for ALI at 60 days was $2.1 \times 10^{-5}$ in the amoxicillin group and $4.7 \times 10^{-5}$ in the fluoroquinolone group (Figure 2). There was an increased risk of ALI associated with fluoroquinolone use, with an HR of 2.32 (95% CI, 1.01–5.35). The adjusted absolute risk difference for use of fluoroquinolones as compared to amoxicillin in the 60-day period was 4.94 (95% CI, .04–16.3) per 1 million episodes. The 60-day risk period was divided into 10-day intervals to explore the timing of the association (Table 2); of the 18 cases of ALI in fluoroquinolone users, 12 (67%) occurred in the first 30 days.

**Subgroup Analyses**
Table 3 includes an overview of the subgroups age and sex; there were no observed differences in these subgroups. There was a trend toward increased risk for men in the older (45–85 years) age group; however, the data did not provide strong enough evidence to support this observation.

**Secondary Analyses**
There was a difference in the estimated risk of all-cause mortality between the groups in the main (1–60), interval with 609 deaths in the fluoroquinolone group compared to 796 deaths in the amoxicillin group (HR, 0.79 [95% CI, .72–.88]). The difference was primarily seen in the 1- to 30-day period (HR, 0.70 [95% CI, .61–.79]) and not in the 31- to 60-day period (HR, 1.02 [95% CI, .85–1.22]).

**DISCUSSION**
In this nationwide propensity score–matched cohort study from Sweden, we found a 2-fold increased risk of ALI associated with fluoroquinolone treatment within a 60-day period after start of treatment. The absolute risk was estimated to be 5 additional events of ALI per 1 million episodes of treatment.

Despite previous safety concerns, only a few studies have assessed the association with ALI in a larger clinical setting [24]. A nested case-control study from Canada including only elderly participants (>66 years of age) reported an odds ratio (OR) of 2.2 for moxifloxacin and an OR of 1.9 for levofloxacin compared to clarithromycin during a follow-up period of 30 days [25]. However, the study lacked information on concurrent drug use and cause of death, factors that potentially confound the outcome of interest. In a retrospective cohort study based on an American insurance claims database, an increased risk for ALI was reported for current use, both for levofloxacin (Relative Risk [RR], 3.2) and for moxifloxacin (RR, 2.3) compared to controls at risk for liver injury [26]. In this study, however, no active comparator drug was used, so it cannot be ruled out that the observed increased risk was attributable to either the acute infection itself or other unmeasured factors associated with filling an antibiotic prescription. In addition, there was a substantial difference in baseline characteristics between cases and controls that were matched on age and sex alone. Furthermore, a North American case-control study based on Veterans Affairs data investigated the risk of ALI associated with fluoroquinolones,

![Figure 2](image-url)  
*Figure 2.* Cumulative incidence of acute liver injury (ALI), fluoroquinolones vs amoxicillin, 1–60 days.

Table 2. Number of Events of Acute Liver Injury Within the 60-Day Risk Period, Divided Into 10-Day Intervals Since Treatment Start

| Interval, d | Oral Fluoroquinolones* (n = 419930) | Oral Amoxicillin (n = 419930) |
|------------|-------------------------------------|-----------------------------|
| 1–10       | 11                                  | 2                           |
| 11–20      | 1                                   | 1                           |
| 21–30      | 0                                   | 2                           |
| 31–40      | 4                                   | 1                           |
| 41–50      | 2                                   | 0                           |
| 51–60      | 0                                   | 2                           |

Data are presented as number of events.

*Fluoroquinolone episodes were propensity score matched 1:1 with amoxicillin on 43 different covariates.

Table 3. Subgroup Analyses of Risk of Acute Liver Injury With Oral Fluoroquinolones Compared With Amoxicillin Use

| Analyses                  | Fluoroquinolones | Amoxicillin | HR (95% CI) | P Value |
|---------------------------|-------------------|-------------|--------------|---------|
| Main interval (1–60 d)    |                   |             |              |         |
| Cases of ALI, No. 10,000 PY | 18                 | 8           | 2.32 (1.01–5.35) | .09     |
| Sex                       |                   |             |              |         |
| Women                     | 6                  | 4           | 1.54 (1.34–5.46) | .42     |
| Men                       | 12                 | 4           | 3.11 (1.00–9.65) |         |
| Age, y                    |                   |             |              |         |
| 40–64                     | 8                  | 6           | 1.75 (1.47–2.94) | .14     |
| 65–85                     | 10                 | 2           | 5.22 (1.14–23.83) | .04     |

Abbreviations: ALI, acute liver injury; CI, confidence interval; HR, hazard ratio; IR, incidence rate; PY, person-years.
and reported an increased risk in users of ciprofloxacin (OR, 1.3) but not in users of levofloxacin and moxifloxacin [27]. The control group in this study was based on patients admitted for myocardial infarction, resulting in a noticeable difference in baseline characteristics between the groups. Also, the cohorts were predominantly male, which could further reduce the external validity. Nevertheless, our results align with these reports, supporting our findings. In addition to previous reports, our study provides some degree of characterization of the timing of this association, suggesting that the risk associated with fluoroquinolones might be most pronounced in the first 10 days after start of treatment; this would correspond to when treatment is ongoing [28].

This study has several strengths. First, the cohorts were based on Swedish national registries with near-complete data coverage, assuring that the results have high representativeness. It has been estimated that the underreporting of data in the Swedish National Inpatient Register is <1% [29]. Second, we used several different strategies to minimize confounding. To control for confounding by indication, we used an active comparator drug without known hepatic toxicity [12]. To balance populations on a large range of underlying differences in health factors, we applied a propensity score–matching model. We excluded patients with severe illnesses to reduce the impact of individuals at high-risk of ALI irrespective of fluoroquinolone treatment. Finally, we also excluded individuals with prior antibiotic prescription or hospitalization as well as individuals with previous history of liver-related illnesses (acute and chronic). This reduced the risk of including individuals at higher risk of the outcome due to underlying illnesses as well as to the fact that we have no information on any treatment initiated during hospital stay. However, residual confounding from lifestyle factors such as alcohol consumption or substance abuse cannot be ruled out. A limitation of this study is that the outcome diagnoses were not formally validated. General validation studies from the Swedish Patient Register suggest that 90%–100% of the diagnoses are correctly coded [29]. A positive predictive value (PPV) of 95% for drug-induced hepatotoxicity was reported in a large study based on Canadian health databases [21]. Additionally, the selected outcome diagnoses used in this study were recently validated in a Danish setting (PPV, 74% [95% CI, 60%–85%]) [20]. Nonetheless, misclassification of the outcome (as reflected in a low PPV) would most likely affect exposed and nonexposed nondifferentially and typically bias the estimate toward null, thus not changing our conclusions [30].

Another limitation is that this study lacked information on the duration of treatment; however, current national recommendations suggest treatments in the range of 7–14 days [28]. Additionally, although the study lacked information on the indication of treatment, the distribution of causes of death in the 2 groups were similar, with pneumonia (ICD-10 code J189) as the leading cause of death in both groups. The possibility that initial symptoms of ALI are misinterpreted and patients are prescribed fluoroquinolones (ie, protopathic bias) cannot be ruled out. However, it seems unlikely that this would lead to biased results because of the low probability of a bacterial infection being the cause of the patient’s clinical status upon presenting with symptoms of liver failure [31].

When analyzing the risk of all-cause mortality in the 2 groups used in our study, we noted a reduced risk among individuals receiving fluoroquinolones primarily in the 1- to 30-day interval. The difference was slight and not present in the second time interval (31–60 days). The difference could be an indication that amoxicillin is prescribed to patients suffering from more severe infections. This scenario is not unlikely considering that amoxicillin is prescribed to a somewhat wider range of indications compared to fluoroquinolones. This observed difference would, however, lead to an underestimation of the main result rather than the opposite. Considering the balance of covariates in the matched cohort and the similarities of causes of death between the 2 groups, this finding should not hamper the main conclusion of this report. In the present study, the majority of treatment courses with fluoroquinolones consisted of ciprofloxacin, which is why the results are primarily applicable to this fluoroquinolone.

In conclusion, this nationwide cohort study found a 2-fold increased risk of ALI associated with fluoroquinolone treatment. The absolute risk is low, which should be taken into consideration when weighing cost vs benefit on an individual level. However, the worldwide and extensive use of fluoroquinolones must also be taken into regard. Further studies are required to elucidate the potential mechanisms behind these reactions. Naturally, the low absolute risk needs to be taken into consideration when weighing cost vs benefit of initiating treatment with these drugs. Nevertheless, the scope of the worldwide and extensive use of fluoroquinolones is substantial and also must be factored into the overall picture.

**Supplementary Data**

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

**Notes**

**Author Contributions.** O. N. contributed to conceptualization, data acquisition, methodology, data and statistical analysis, and writing of the original draft and preparation. H. S. contributed to data acquisition, methodology, data and statistical analysis, review, and editing. M. I. contributed to conceptualization, methodology, resources, supervision, review, and editing.

**Acknowledgments.** The authors thank Dr Björn Pasternak, MD, PhD (Karolinska Institutet) for his valuable contributions.

**Disclaimer.** The funders played no role in the design of the study, data collection or analysis, preparation of the manuscript, or decision to submit the manuscript for publication.

---

*Fluoroquinolones and Acute Liver Injury. CID 2022;74 (15 June) 2157*
**Financial support.** This work was supported by grants from the Swedish Government Funds for Clinical Research; the Scandinavian Society for Antimicrobial Chemotherapy Foundation; the Royal Physiological Society in Lund; and the Elsa Lundberg and Greta Fleron foundation.

**Potential conflicts of interest.** H. S. received consulting fees from Celgene and employment with IQVIA, outside the submitted work. All other authors report no potential conflicts of interest.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**

1. Ostapowicz G, Fontana RJ, Schiedt FV, et al; US Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137:947–54.

2. Björnsson ES. Drug-induced liver injury due to antibiotics. Scand J Gastroenterol 2017; 52:617–23.

3. Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144:1419–25, 1425.e1–3; quiz e19–20.

4. Sgro C, Cilnard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36:451–5.

5. Centers for Disease Control and Prevention. Antibiotic resistance and patient safety portal. Available at: https://arpsp.cdc.gov/profile/antibiotic-use/214. Accessed 17 March 2021.

6. Hoope DC, Jacoby GA. Topoisomerase inhibitors: fluoroquinolones mechanisms of action and resistance. Cold Spring Harb Perspect Med 2016; 6:a025320.

7. Tsai WC, Yang YM. Fluoroquinolone-associated tendinopathy. Chang Gung Med J 2011; 34:461–7.

8. Gorelik E, Masarwa R, Perlman A, et al. Fluoroquinolones and cardiovascular risk: a systematic review, meta-analysis and network meta-analysis. Drug Saf 2019; 42:529–38.

9. Singh S, Nautiyal A. Aortic dissection and aortic aneurysms associated with fluoroquinolones: a systematic review and meta-analysis. Am J Med 2017; 130:1449–1457.e9.

10. Lucena MI, Andrade RJ, Rodgers L, et al. Trovafloxacin-induced acute hepatitis. Clin Infect Dis 2000; 30:400–1.

11. National Institute of Diabetes and Digestive and Kidney Diseases. Fluoroquinolones. In: LiverTox: clinical and research information on drug-induced liver injury. Bethesda, MD: NIH, 2012.

12. Andrade RJ, Tulkens PM. Hepatic safety of antibiotics used in primary care. J Antimicrob Chemother 2011; 66:1431–46.

13. National Institute of Diabetes and Digestive and Kidney Diseases. Aminoglycins. In: LiverTox: clinical and research information on drug-induced liver injury. Available at: https://www.ncbi.nlm.nih.gov/books/NBK547854/. Accessed 24 September 2021.

14. Wetermark B, Hammar N, Fored CM, et al. The new Swedish Prescribed Drug Register—opportunities for pharmacopoeidemological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16:726–35.

15. Socialstyrelsen. The national patient register. https://www.socialstyrelsen.se/en/statistics-and-data/registers/register-information/the-national-patient-register/. Accessed 24 September 2021.

16. Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Proceedings of the 26th Annual SAS Users Group International Conference, 2001. Paper 214-26. Available at: www2.sas.com/proceedings/ug11/.

17. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 2015; 34:3661–79.

18. D’Agostino RB, Rubin DB. Estimating and using propensity scores with partially missing data. J Am Stat Assoc 2000; 95:749–59.

19. Orman ES, Conejeras RM, Vuppallanchi R, et al. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol 2011; 9:517–23.e3.

20. Forns J, Caimosa-Achirica M, Hellfritzsch M, et al. Validity of ICD-9 and ICD-10 codes used to identify acute liver injury: a study in three European data sources. Pharmacoepidemiol Drug Saf 2019; 28:965–75.

21. Myers RP, Leung Y, Shaheen AA, Li B. Validation of ICD-9-CM/ICD-10 coding algorithms for the identification of patients with acetaminophen overdose and hepatotoxicity using administrative data. BMC Health Serv Res 2007; 7:159.

22. Collett D. Modelling survival data in medical research. Third ed. Boca Raton, FL: CRC Press, 2013.

23. Svensström H, Pautenak B, Hvid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med 2013; 368:1704–12.

24. Björnsson ES, Hoofnagle JH. Categorization of drugs implicated in causing liver injury: critical assessment based on published case reports. Hepatology 2016; 63:590–603.

25. Paterson JM, Mamdani MM, Manno M, Juurlink DN; Canadian Drug Safety and Effectiveness Research Network. Fluoroquinolone therapy and idiosyncratic acute liver injury: a population-based study. CMAJ 2012; 184:1565–70.

26. Kaye JA, Castellague I, Bui CL, et al. Risk of acute liver injury associated with the use of moxifloxacin and other oral antimicrobials: a retrospective, population-based cohort study. Pharmacotherapy 2014; 34:336–49.

27. Aishamami TM, Larrat EP, Morrill HJ, Caffrey AR, Quilliam BJ, LaPlante KL. Risk of hepatotoxicity associated with fluoroquinolones: a national case-control safety study. Am J Health Syst Pharm 2014; 71:37–43.

28. Folkhälsomyndigheten. Behandlingsrekommendationer för vanliga infektioner i öppenvård. 2021. Available at: https://www.folkhalsomyndigheten.se/publicerat-material/publikationsarkiv/b/behandlingsrekommendationer-for-vanliga-infektioner-i-oppenvard/. Accessed 24 September 2021.

29. Ludvigson JF, Andersson E, Ekholm B, et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2013; 11:450.

30. Newcombe SR, Xu S, Kulldorff M, Daley MF, Fireman B, Glanz JM. A primer on quantitative bias analysis with positive predictive values in research using electronic health data. J Am Med Inform Assoc 2019; 26:1664–74.

31. Roy-Chowdhury NP, Roy-Chowdhury J. Diagnostic approach to the adult with jaundice or asymptomatic hyperbilirubinemia. 2020. Available at: https://uptodate.com/contents/diagnostic-approach-to-the-adult-with-jaundice-or-asymptomatic-hyperbilirubinemia. Accessed 24 September 2021.